Efficacy of Rivastigmine in Alzheimer’s disease- A structured seview

Abstract

Rivastigmine is an anti-cholinesterase agent, used to treat mild to moderate dementia of Alzheimer’s disease (AD). Its efficacy and tolerability increase the treatment compliance. This study focused on determining the efficacy of Rivastigmine by reviewing data from the clinical trials. A structured search was conducted through PubMed up to September 2022 to identify randomized controlled trails (RCT) evaluating the efficacy of oral capsule and transdermal patch of Rivastigmine for AD. The efficacy was assessed using the primary end point, Alzheimer's Disease Assessment Scale–Cognitive Subscale (ADAS-cog) and secondary end point, Mini Mental State Examination (MMSE). It was suggested that Rivastigmine capsule 12 mg/d (twice daily) and Rivastigmine patch 9.5 mg/d (Once daily) is the optimal dose for 24 weeks in mild to moderate AD. Though cholinesterase inhibitors have limited activity, Rivastigmine still represents a positive effect for the treatment of AD.